Amicogen Inc enters into agreement to divest its ownership in Bio-Works

Amicogen Inc. has entered into an agreement to divest its ownership in Bio-Works Technologies AB (BIOWKS.ST). Amicogen's entire holding of 3,007,896 shares was sold today at 12:03:42 CET in a transaction brokered by Erik Penser Bank for a price of 15.75 SEK. As of June 30, 2021, Amicogen Inc. was Bio-Works' second largest shareholder. The block was primarily sold to Nortal Investments AB and Calyptra AB. As of June 30, 2021, Nortal Investments AB was Bio-Works largest shareholder, owning 4,119,885 shares, or 13.6% of the company. 

Dr. Shin, CEO of Amicogen Inc., stated “Amicogen was an early investor in Bio-Works, and over time the relationship between the two companies has grown. Amicogen is currently Bio-Works’ exclusive distributor in the Korean market, its supplier of the alkali-stable protein A ligand used in WorkBeads affimAb, and the recipient of a technology transfer project to establish domestic production of agarose resins in Korea. Now, the time was right for Amicogen to divest its ownership in Bio-Works, but the two companies will continue to work together on many fronts. Amicogen will build a chromatography resin factory in Korea with the proceeds of this transaction to meet the increasing demand for resins from customers together Bio-Works.”

For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Jonathan Royce, CEO, e-mail: jonathan.royce@bio-works.com, phone: +46 70 1434143.

Bio-Works designs, develops, manufactures and supplies innovative leading-edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. Bio-Works’ agarose based high performance products are used for purification in the life science research phases as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. The Bio-Works’ headquarter with R&D and manufacturing is located in Uppsala Business Park in Uppsala, Sweden and the company processes and a Quality Management System follows the standards of ISO 9001:2015. The company’s share is listed on Nasdaq First North. FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Adviser.

Subscribe

Documents & Links